Literature DB >> 2943753

Plasma levels of atrial natriuretic peptide in primary aldosteronism and essential hypertension.

T Yamaji, M Ishibashi, H Sekihara, F Takaku, H Nakaoka, J Fujii.   

Abstract

Plasma levels of atrial natriuretic peptide (ANP) were measured in 9 patients with primary aldosteronism and 41 patients with essential hypertension (class I or II by WHO classification) using a specific and sensitive RIA. The mean plasma ANP concentration in patients with primary aldosteronism (mean +/- SEM, 67.1 +/- 10.8 pg/ml; n = 9) was significantly higher than that in healthy normotensive subjects (37.9 +/- 1.4 pg/ml; n = 108) or patients with essential hypertension (38.5 +/- 2.8 pg/ml; n = 41). During treatment with spironolactone, plasma levels of ANP declined in 6 of the 7 patients with primary aldosteronism, but no change occurred in the remaining patient who had cardiac enlargement of unknown etiology. The mean plasma ANP concentration in patients with essential hypertension, on the other hand, was not significantly different from that in normal subjects. These results indicate that plasma ANP levels are elevated in patients with primary aldosteronism, probably due to volume expansion, whereas no abnormality in ANP secretion exists in patients with uncomplicated essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2943753     DOI: 10.1210/jcem-63-4-815

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  [Atrial natriuretic peptide and its significance for arterial hypertension].

Authors:  G Wambach; M Stimpel; G Bönner
Journal:  Klin Wochenschr       Date:  1989-11-03

2.  Natriuretic peptides receptors in human aldosterone-secreting adenomas.

Authors:  R Sarzani; G Opocher; M V Paci; A S Belloni; F Mantero; P Dessì-Fulgheri; A Rappelli
Journal:  J Endocrinol Invest       Date:  1999 Jul-Aug       Impact factor: 4.256

3.  Lack of aldosterone inhibition by atrial natriuretic factor in primary aldosteronism: in vitro studies.

Authors:  S Rocco; G Opocher; D D'Agostino; L Leone; F Mantero
Journal:  J Endocrinol Invest       Date:  1989-01       Impact factor: 4.256

4.  Distribution of atrial natriuretic peptide in the conduction system and ventricular muscles of the human heart.

Authors:  N Mochizuki; H Sawa; H Yasuda; T Shinohara; K Nagashima; T Yamaji; N Ohnuma; W W Hall
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

5.  Increased cyclic guanosine monophosphate production and overexpression of atrial natriuretic peptide A-receptor mRNA in spontaneously hypertensive rats.

Authors:  J Tremblay; C Huot; R C Willenbrock; F Bayard; F Gossard; N Fujio; C Koch; O Kuchel; W Debinski; P Hamet
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

6.  The effect of indomethacin on basal and saline-stimulated plasma atrial natriuretic factor levels in normal man.

Authors:  J A McKnight; G Roberts; B Sheridan; A B Atkinson
Journal:  Ir J Med Sci       Date:  1991-07       Impact factor: 1.568

7.  Changes in urinary kallikrein excretion and plasma natriuretic factor in a patient with primary aldosteronism with special reference to adrenal histology.

Authors:  S Hayami; T Nakada; H Kakizaki; T Yagisawa; H Kaneko; Y Iijima; H Obata; M Miura
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

8.  Atrial natriuretic peptide (ANP) in patients with chronic renal failure on maintenance haemodialysis.

Authors:  R de Châtel; J Makó; M Tóth; I Barna; R E Lang
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.